| Jay Kincannon, MD | |
|
1 Childrens Way # 653, Little Rock, AR 72202-3500 | |
| (501) 364-1100 | |
| (501) 526-5148 |
| Full Name | Jay Kincannon |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 39 Years |
| Location | 1 Childrens Way # 653, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184711236 | NPI | - | NPPES |
| 119266001 | Medicaid | AR | |
| 370005986 | Other | AR | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NP0225X | Dermatology - Pediatric Dermatology | C-6844 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uams Medical Center | Little rock, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Arkansas | 4082528955 | 1121 |
News Archive
The current assumed pedestrian walking speed of 1.2 m per second should be revised, say researchers whose findings show that the average UK resident over the age of 65 years does not walk at this pace.
Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.
Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.
In new research published in the April 4, 2013 issue of The American Journal of Human Genetics, researchers from Brigham and Women's Hospital demonstrate that some variants in our genes that could put a person at risk for inflammatory diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis, have been the target of natural selection over the course of human history.
Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.
› Verified 8 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588654016 PECOS PAC ID: 4082528955 Enrollment ID: O20031219000706 |
News Archive
The current assumed pedestrian walking speed of 1.2 m per second should be revised, say researchers whose findings show that the average UK resident over the age of 65 years does not walk at this pace.
Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.
Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.
In new research published in the April 4, 2013 issue of The American Journal of Human Genetics, researchers from Brigham and Women's Hospital demonstrate that some variants in our genes that could put a person at risk for inflammatory diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis, have been the target of natural selection over the course of human history.
Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.
› Verified 8 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346230968 PECOS PAC ID: 4082528955 Enrollment ID: O20040115000431 |
News Archive
The current assumed pedestrian walking speed of 1.2 m per second should be revised, say researchers whose findings show that the average UK resident over the age of 65 years does not walk at this pace.
Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.
Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.
In new research published in the April 4, 2013 issue of The American Journal of Human Genetics, researchers from Brigham and Women's Hospital demonstrate that some variants in our genes that could put a person at risk for inflammatory diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis, have been the target of natural selection over the course of human history.
Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.
› Verified 8 days ago
| Entity Name | Arkansas Childrens Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598773079 PECOS PAC ID: 2769477744 Enrollment ID: O20040419000796 |
News Archive
The current assumed pedestrian walking speed of 1.2 m per second should be revised, say researchers whose findings show that the average UK resident over the age of 65 years does not walk at this pace.
Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.
Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.
In new research published in the April 4, 2013 issue of The American Journal of Human Genetics, researchers from Brigham and Women's Hospital demonstrate that some variants in our genes that could put a person at risk for inflammatory diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis, have been the target of natural selection over the course of human history.
Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jay Kincannon, MD 1 Childrens Way # 653, Little Rock, AR 72202-3500 Ph: (501) 364-1100 | Jay Kincannon, MD 1 Childrens Way # 653, Little Rock, AR 72202-3500 Ph: (501) 364-1100 |
News Archive
The current assumed pedestrian walking speed of 1.2 m per second should be revised, say researchers whose findings show that the average UK resident over the age of 65 years does not walk at this pace.
Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.
Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.
In new research published in the April 4, 2013 issue of The American Journal of Human Genetics, researchers from Brigham and Women's Hospital demonstrate that some variants in our genes that could put a person at risk for inflammatory diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis, have been the target of natural selection over the course of human history.
Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.
› Verified 8 days ago
Dr. Michael Frederick Osleber, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9601 Baptist Health Dr Ste 860, Little Rock, AR 72205 Phone: 501-975-7455 Fax: 501-975-3631 | |
Terri Lynn Martin, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 16115 Saint Vincent Way, Suite 300, Little Rock, AR 72223 Phone: 501-817-3923 Fax: 501-817-3930 | |
Dr. Jacey Tanner Guthrie, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4200 N Rodney Parham Rd Ste 202, Little Rock, AR 72212 Phone: 501-227-4323 Fax: 501-227-4149 | |
Dr. Lindsay Anne Lipke, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9601 Baptist Health Dr, Suite 690, Little Rock, AR 72205 Phone: 501-227-8422 Fax: 501-537-2399 | |
Dr. Brian Scott Wayne, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 S University Ave, Suite 301, Little Rock, AR 72205 Phone: 501-664-4161 | |
Garrett James Nelson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9601 Baptist Health Dr Ste 690, Little Rock, AR 72205 Phone: 501-227-8422 |